UNSPSC 51453101: Morantel

This classification denotes an antihelminthic agent with the molecular formula C12H16N2S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 7NJ031HAX5 chemically known as (e)-1,4,5,6-tetrahydro-1-methyl-2-(2-(3-methyl-2-thienyl)vinyl)pyrimidine but generally known as morantel, which bears US NIH Compound Identifier 5353792. European Medicines Agency schedules Morantel in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09063MIG. The term MORANTEL is an International Non-Proprietary Name or INN.

Most nations schedule morantel under HS 29349990 and SITC 51579. As of Q4 2014, MORANTEL remains the US FDA Preferred Term for this commodity. Morantel bears US NLM identifiers UMLS ID C0026534 and NCI Concept Code C75221. SMILES: CC1=C(SC=C1)/C=C/C2=NCCCN2C.

UNSPSC 51453101 Morantel, a Commodity code, does not align with recent state and local procurement activity. The code nominally describes morantel, a veterinary anthelmintic, yet the two recent opportunities tagged under it involve pharmaceutical procurement unrelated to morantel: a completed Illinois Department of Public Health award to Chartwell Rx LLC for Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets through the MMCAP Infuse cooperative purchasing consortium, and a Seminole County, Florida IFB for Naloxone and Safe Drug Deactivation Systems. Neither solicitation involves morantel products or veterinary pharmaceuticals.

The mismatch between the code's nominal scope and the opportunities tagged to it suggests either miscoding by issuing bodies or that state and local procurement systems are using this UNSPSC category as a catch-all for pharmaceutical warehouse and emergency-response drug purchases. The Illinois award ($2,999,999.11 over 12 months with two one-year renewal options to Chartwell Rx LLC) and the Seminole County opportunity (1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, IFB released June 30, 2026, response due July 26, 2026) show activity concentrated in health-department and county-health procurement. Without additional opportunities clearly scoped to morantel itself, this code presents minimal signal for pursuing morantel supply or veterinary pharmaceutical contracts at the state and local level under its current designation.